Rosuvastatin in Older Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical benefit of adding ezetimibe was consistent across patient subgroups [299,444] and also led to a reduction of total CV events [445], stroke [446], and rehospitalizations [447].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [445]
In the citing paper
“The Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico-Effect of Rosuvastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in patients with symptomatic HF did not demonstrate any benefit on CV mortality and non-fatal MI and stroke, in spite of a marked reduction of LDL-C and hs-CRP.36,39”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [36]
In the citing paper
“In two large RCTs 373,374 there was no benefit on hard endpoints, such as CV mortality and non-fatal MI and stroke, in spite of a decrease in hospitalizations 373,375 and a marked reduction of LDL-C and hs-CRP in patients with mainly systolic heart failure.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [373]
In the citing paper
“Trials of low‐dose anticoagulation, 4 PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, 5 as well as statins 2 , 6 in patients with HF have been disappointing to date”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
In the citing paper
“Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease (ASCVD), 1 , 2 as designated by professional society guidelines. 3”
From Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT (2022) · cites this paper as [2]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Self-citationSacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citationThe Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 533
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Inhalation of levomepromazine in severe acute asthma
Pedersen, J. E., Olsen, A., & Banning, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91755-8 · Cited by 390
Cited by
Items 301–400 of 1,000
Rafeh, R. W., Viveiros, A., Oudit, G. Y., & EL‐Yazbi, A. F. (2020) · Clinical Science · doi:10.1042/cs20190227 · Cited by 66
Hopper, I., Samuel, R., Hayward, C., Tonkin, A., & Krum, H. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.04.013 · Cited by 67
Patel, P. J., Khera, A. V., Wilensky, R. L., & Rader, D. J. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft084 · Cited by 63
Comorbidities in Heart Failure
van der Wal, H. H., van Deursen, V. M., van der Meer, P., & Voors, A. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_27 · Cited by 74
Pleiotropic Effects of Statins: Evidence for Benefits Beyond LDL-Cholesterol Lowering
Marzilli, M. (2010) · American Journal of Cardiovascular Drugs · doi:10.2165/1153644-s0-000000000-00000 · Cited by 65
Cardiac biomarkers in heart failure
Liquori, M. E., Christenson, R. H., Collinson, P. O., & deFilippi, C. R. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.01.032 · Cited by 70
Oxidative Stress and Heart Failure in Altered Thyroid States
Mishra, P., & Samanta, L. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/741861 · Cited by 65
Diabetes Secondary to Treatment with Statins
Laakso, M., & Kuusisto, J. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0837-8 · Cited by 67
Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life
Gastelurrutia, P., Lupón, J., de Antonio, M., Urrútia, A., Díez, C., Coll, R., Altimir, S., & Bayés‐Genís, A. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.02.018 · Cited by 59
Chang, S., Kim, Y.-J., Lee, H., Kim, D., Kim, H., Chang, H., Sohn, D., Oh, B., & Park, Y.-B. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131243 · Cited by 59
2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures
Drozda, J. P., Ferguson, T. B., Jneid, H. M., Krumholz, H. M., Nallamothu, B. K., Olin, J. W., & Ting, H. H. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.003 · Cited by 63
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
Bayés‐Genís, A., Núñez, J. E., Zannad, F. M., Ferreira, J. P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., Lang, C. C., Ng, L. L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.057 · Cited by 61
Self-citationHigh-density Lipoprotein Cholesterol Levels and Prognosis in Advanced Heart Failure
Mehra, M. R., Uber, P. A., Lavie, C. J., Milani, R. V., Park, M., & Ventura, H. O. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.04.026 · Cited by 58
Telomere Biology in Heart Failure
Wong, L. S. M., de Boer, R. A., Samani, N. J., van Veldhuisen, D. J., & van der Harst, P. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.007 · Cited by 58
The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Nakou, E. S., Liberopoulos, E. N., Milionis, H. J., & Elisaf, M. (2008) · Current Vascular Pharmacology · doi:10.2174/157016108785909733 · Cited by 59
Anti-inflammatory effect of physical training in heart failure: role of TNF-alpha and IL-10.
Júnior, M. L. B., Júnior, M. L. B., Lópes, R. D., Seelaender, M. C. L., & Lopes, A. C. (2009) · PubMed · Cited by 65
Wang, H. J., Park, J. Y., Kwon, O., Choe, E. Y., Kim, C. H., Hur, K. Y., Lee, M., Yun, M., Soo, B., Kim, Y., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1091139 · Cited by 67
Fukuta, H., Goto, T., Wakami, K., & Ohte, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.186 · Cited by 66
Bielecka-Dabrowa, A., Bytyçi, I., Von Haehling, S., Anker, S., Jozwiak, J., Rysz, J., Hernandez, A. V., Bajraktari, G., Mikhalidis, D. P., & Banach, M. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1135-z · Cited by 57
Smilde, T. D. J., van Veldhuisen, D. J., & van den Berg, M. P. (2009) · Clinical Research in Cardiology · doi:10.1007/s00392-009-0747-0 · Cited by 57
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 69
VersorgungsLeitlinie, N. (2011) · Cited by 58
Feinstein, M. J., Jhund, P., Kang, J., Ning, H., Maggioni, A., Wikstrand, J., Kjekshus, J., Tavazzi, L., McMurray, J., & Lloyd-Jones, D. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.247 · Cited by 56
Self-citationde Berrazueta, J. R., Guerra-Ruiz, A. R., García‐Unzueta, M. T., Toca, G. M., Laso, R. S., Herrero, M. S. D. A., Martín, M. A. C., Cobo, M., & Llorca, J. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq036 · Cited by 59
Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., Garjani, A., & Maleki‐Dizaji, N. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.061 · Cited by 57
C-reactive protein is a bystander of cardiovascular disease
Anand, S. S., & Yusuf, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq242 · Cited by 56
Zhao, H., Liao, Y., Minamino, T., Asano, Y., Asakura, M., Kim, J., Asanuma, H., Takashima, S., Hori, M., & Kitakaze, M. (2008) · Hypertension Research · doi:10.1291/hypres.31.1977 · Cited by 62
“Noticeably, a recent report showed that rosuvastatin treatment reduced the total number of heart failure hospitalizations in a large-scale randomized double-blind placebo-controlled trial (35).”
BackgroundAimo, A., Januzzi, J. L., Vergaro, G., Richards, M., Lam, C. S. P., Latini, R., Anand, I. S., Cohn, J. N., Ueland, T., Gullestad, L. L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1701 · Cited by 56
“…( * ), RR values could not be computed as no events were observed in the reference category. as a consequence of the inclusion of several trials (for example, LVEF < 40% in the Valsartan Heart Failure Trial, 32 or ≤ 40% in the Controlled Rosuvastatin Multinational Trial in Heart Failure 33 ).”
BackgroundInfluentialSelf-citationStumpf, C., Petzi, S., Seybold, K., Wasmeier, G., Arnold, M., Raaz, D., Yilmaz, A., Daniel, W. G., & Garlichs, C. D. (2009) · Clinical Science · doi:10.1042/cs20080042 · Cited by 55
Tousoulis, D., Oikonomou, E. K., Siasos, G., Chrysohoou, C. A., Zaromitidou, M., Kioufis, S., Maniatis, K., Dilaveris, P., Miliou, A., Michalea, S., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.015 · Cited by 55
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 107
Uijl, A., Koudstaal, S., Vaartjes, I., Boer, J. M. A., Verschuren, W. M. M., van der Schouw, Y. T., Asselbergs, F. W., Hoes, A. W., & Sluijs, I. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.03.009 · Cited by 55
Liu, M., Wang, F., Wang, Y., & Jin, R. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6186-3 · Cited by 54
The Success Story of LDL Cholesterol Lowering
Pedersen, T. R. (2016) · Circulation Research · doi:10.1161/circresaha.115.306297 · Cited by 59
Milionis, H. J., Ntaios, G., Korompoki, E., Vemmos, K. N., & Michel, P. (2019) · International Journal of Stroke · doi:10.1177/1747493019873594 · Cited by 61
“one restricted to renal transplant recipients,(12) one to hemodialysis patients(13) and one to patients with systolic heart failure.(14)”
BackgroundBonsu, K. O., Reidpath, D. D., & Kadirvelu, A. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12150 · Cited by 56
Recent Insights Into the Role of Autoimmunity in Idiopathic Dilated Cardiomyopathy
Lappé, J. M., Pelfrey, C. M., & Tang, W. H. W. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.02.016 · Cited by 59
de Lorgeril, M., Salen, P., Defaye, P., & Rabaeus, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-5 · Cited by 55
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
Koh, K. K., Quon, M. J., Sakuma, I., Han, S. H., Choi, H., Lee, K., & Shin, E. K. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.028 · Cited by 55
Cai, R., Yuan, Y., Zhou, Y., Xia, W., Wang, P., Sun, H., Yang, Y., Huang, R., & Wang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104922 · Cited by 57
Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Bocci, V. A., Zanardia, I., Valacchi, G., Borrelli, E., & Travagli, V. (2015) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x1502151209114642 · Cited by 61
Kizer, J. R., Madias, C., Wilner, B., Vaughan, C. J., Mushlin, A. I., Trushin, P., Gotto, A. M., & Pasternak, R. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.051 · Cited by 52
Lipid lowering for primary prevention
Yusuf, S., Lonn, E., & Bosch, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60357-3 · Cited by 54
Estatinas e stresse oxidativo na insuficiência cardíaca crónica
Torres-Costa, S., Reina‐Couto, M., Albino‐Teixeira, A., & Sousa, T. (2016) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2015.09.006 · Cited by 59
Cholesterol-Lowering Agents: Statins—For Everyone?
Hadjiphilippou, S., & Ray, K. K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313245 · Cited by 49
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 72
Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure
Askevold, E. T., Gullestad, L. L., Dahl, C. P., Yndestad, A., Ueland, T., & Aukrust, P. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0185-9 · Cited by 52
Self-citationWessler, B. S., Kramer, D. G., Kelly, J. L., Trikalinos, T. A., Kent, D. M., Konstam, M. A., & Udelson, J. E. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.961573 · Cited by 51
Pons, F., Lupón, J., Urrútia, A., González, B., Crespo, E., Díez, C., Cano, L., Cabanes, R., Altimir, S., Coll, R., et al. (2010) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(10)70063-3 · Cited by 51
Rahimi, K., Majoni, W., Merhi, A., & Emberson, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs005 · Cited by 54
Riaz, H., Khan, A. R., Khan, M. S., Rehman, K. A., Alansari, S. A. R., Gheyath, B., Raza, S., Barakat, A., Luni, F. K., Ahmed, H., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.046 · Cited by 50
Vonbank, A., Drexel, H., Agewall, S., Lewis, B. S., Dopheide, J. F., Kjeldsen, K. P., Ceconi, C., Savarese, G., Rosano, G. M. C., Waßmann, S., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy028 · Cited by 51
Judge, C., Ruttledge, S., Costello, M., Murphy, R., Loughlin, E., Alvarez-Iglesias, A., Ferguson, J., Gorey, S., Nolan, A., Canavan, M., et al. (2019) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2019.02.018 · Cited by 50
Takano, H., Mizuma, H., Kuwabara, Y., Sato, Y., Shindo, S., Kotooka, N., Fujimatsu, D., Kobayashi, Y., Inoue, T., Node, K., et al. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-1062 · Cited by 51
Rush, C. J., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy407 · Cited by 48
Self-citationLegacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
Nayak, A., Hayen, A. D., Zhu, L., McGeechan, K., Glasziou, P., Irwig, L., Doust, J. A., Gregory, G. A., & Bell, K. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020584 · Cited by 55
Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure
Askevold, E. T., Nymo, S. H., Ueland, T., Gravning, J. A., Wergeland, R., KJEKSHUS, J. K., Yndestad, A., Cleland, J. G. F., McMurray, J. J. V., Aukrust, P., et al. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.972653 · Cited by 50
Self-citationKristensen, S. L., Jhund, P. S., Køber, L., Preiss, D., Kjekshus, J., McKelvie, R. S., Zile, M. R., Anand, I. S., Wikstrand, J., Wedel, H., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.211 · Cited by 49
Self-citationAlehagen, U., Benson, L., Edner, M., Dahlström, U., & Lund, L. H. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001730 · Cited by 49
(2008), G. D. T. D. L. E. P. E. D. Y. T. D. L. I. C. A. Y. C., & Desarrollada en colaboración con la Heart Failure Association (HFA) de la ESC y aprobada por la European Society of Intensive Care Medicine (ESICM) (2008) · Revista Española de Cardiología · doi:10.1016/s0300-8932(08)75740-3 · Cited by 83
Immunomodulation and immunopharmacology in heart failure
Markousis‐Mavrogenis, G., Baumhove, L., Al‐Mubarak, A. A., Aboumsallem, J. P., Bömer, N., Voors, A. A., & van der Meer, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00919-6 · Cited by 52
Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy
Nakamura, M. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12568 · Cited by 61
Statins for the Prevention of Stroke: A Meta-Analysis of Randomized Controlled Trials
Wang, W., & Zhang, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092388 · Cited by 52
Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy
Sharma, H., Pathan, R. A., Kumar, V., Javed, S., & Bhandari, U. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.04.008 · Cited by 48
Pleiotropic effects of the HMG-CoA reductase inhibitors
Santana, O., & Mihos, C. G. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s16779 · Cited by 58
Oghlakian, G. O., Sipahi, İ., & Fang, J. C.-T. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0841 · Cited by 52
Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
Leyva, F., Israel, C. W., & Singh, J. P. (2023) · Circulation · doi:10.1161/circulationaha.122.062159 · Cited by 53
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Jug, B., Salobir, B., Vene, N., Šebeštjen, M., Šabović, M., & Keber, I. (2009) · Heart and Vessels · doi:10.1007/s00380-008-1111-4 · Cited by 50
“In this regard, elevated levels of hsCRP may also be an epiphenomenon that is not directly related to heart failure progression; in fact, the recent CORONA study showed that lowering hsCRP levels with statin therapy in patients with ischemic heart failure does not translate into a reduction of cardiovascular events.(3…”
ResultThe current status of interventions aiming at reducing sudden cardiac death in dialysis patients
de Bie, M. K., van Dam, B., Gaasbeek, A., van Buren, M., van Erven, L., Bax, J. J., Schalij, M. J., Rabelink, T. J., & Jukema, J. W. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp185 · Cited by 47
“This is confirmed by the fact that statin therapy had no effect on SCD in the 4D study(6) and in other statin trials in non-dialysis patient groups, such as in heart failure patients in the CORONA study.(35)”
ResultDrug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
Anyanwagu, U., IDRIS, I. R., & Donnelly, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.274 · Cited by 54
Biomarkers for Chronic Heart Failure: Diagnostic, Prognostic, and Therapeutic Challenges
Lainščak, M., Anker, M. S., von Haehling, S., & Anker, S. D. (2009) · Herz · doi:10.1007/s00059-009-3316-4 · Cited by 45
“Although the large-scale randomized trials CORO-NA and GISSI-HF did not test this hypothesis, they have shown that rosuvastatin was effective in lowering cholesterol in HF patients which failed to convert to a survival benefit [ 44 , 45].”
The Role of Inflammation in the Pathophysiology of Heart Failure
Amara, M., Stoler, O., & Birati, E. Y. (2025) · Cells · doi:10.3390/cells14141117 · Cited by 66
Drozda, J. P., Ferguson, T. B., Jneid, H. M., Krumholz, H. M., Nallamothu, B. K., Olin, J. W., Ting, H. H., ACC/AHA TASK FORCE ON PERFORMANCE MEASURES, Heidenreich, P. A., Albert, N. M., et al. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000014 · Cited by 52
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., Schou, M., Kosiborod, M., Langkilde, A. M., Martínez, F. A., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2124 · Cited by 55
Self-citationYancy, C. W., Fonarow, G. C., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., McBride, M. L., Mehra, M. R., O’Connor, C. M., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.681 · Cited by 46
Peripheral arterial disease and chronic heart failure: a dangerous mix
Inglis, S. C., Hermis, A., Shehab, S., Newton, P. J., Lal, S., & Davidson, P. M. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9331-1 · Cited by 52
“5 % male; mean age 73 years) [30], of which 12.”
Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects
Schmechel, A., Grimm, M. F., El‐Armouche, A., Hoppner, G., Schwoerer, A. P., Ehmke, H., & Eschenhagen, T. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp005 · Cited by 46
Davenport, A., Anker, S. D., Mebazaa, A., Palazzuoli, A., Vescovo, G., Bellomo, R., Ponikowski, P. P., Anand, I. S., Aspromonte, N., Bagshaw, S. M., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq252 · Cited by 49
López-Jiménez, F. A., Simha, V., Thomas, R. J., Allison, T. G., Basu, A., Fernandes, R., Hurst, R. T., Kopecky, S. L., Kullo, I. J., Mulvagh, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.016 · Cited by 49
Bétrisey, S., Haller, M. L., Efthimiou, O., Speierer, A., Giovane, C. D., Moutzouri, E., Blum, M. R., Aujesky, D., Rodondi, N., & Gencer, B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030714 · Cited by 49
Reith, C. A., Blackwell, L. S., Emberson, J., Preiss, D., Spata, E., Davies, K., Halls, H. J., Harper, C., Holland, L., Wilson, K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01578-8 · Cited by 72
Self-citationMechanisms for Cachexia in Heart Failure
Pureza, V. S., & Florea, V. G. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0153-9 · Cited by 46
Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data
Marcks, N., Aimo, A., Januzzi, J. L., Vergaro, G., Clerico, A., Latini, R., Meessen, J. M. T. A., Anand, I. S., Cohn, J. N., Gravning, J. A., et al. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01822-1 · Cited by 49
Ma, Y., Wen, X., Peng, J., Lu, Y., Guo, Z., & Lu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051548 · Cited by 46
Rossi, V. A., Gruebler, M. R., Monzo, L., Galluzzo, A., & Beltrami, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076838 · Cited by 48
The association of statin therapy and cancer: a meta-analysis
Chen, Z., Wu, P., Wang, J., Chen, P., Fang, Z., & Luo, F. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01955-4 · Cited by 48
The Emerging Field of Cardioimmunology: Past, Present and Foreseeable Future
Mann, D. L. (2024) · Circulation Research · doi:10.1161/circresaha.123.323656 · Cited by 53
Dorresteijn, J. A. N., Boekholdt, S. M., van der Graaf, Y., Kastelein, J. J. P., LaRosa, J. C., Pedersen, T. R., DeMicco, D. A., Ridker, P. M., Cook, N. R., & Visseren, F. L. J. (2013) · Circulation · doi:10.1161/circulationaha.112.000712 · Cited by 50
Relative safety profiles of high dose statin regimens
Barrios, V. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2048 · Cited by 48
Self-citationBuber, J., Goldenberg, I., Moss, A. J., Wang, P. J., McNitt, S. A., Hall, W. J., Eldar, M., Barsheshet, A., & Shechter, M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.041 · Cited by 43
Importance of Nonobstructive Coronary Artery Disease in the Prognosis of Patients With Heart Failure
Braga, J. R., Austin, P. C., Ross, H. J., Tu, J. V., & Lee, D. S. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.02.014 · Cited by 48
Epigenetic Therapies for Heart Failure: Current Insights and Future Potential
Napoli, C., Bontempo, P., Palmieri, V., Coscioni, E., Maiello, C., Donatelli, F., & Benincasa, G. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s287082 · Cited by 42
Tehrani, F., Phan, A., Chien, C., Morrissey, R. P., Rafique, A. M., & Schwarz, E. R. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.047 · Cited by 44
Abulhul, E., McDonald, K., Martos, R., Phelan, D. M. J., Spiers, P., Hennessy, M., Baugh, J. A., Watson, C. J., O’Loughlin, C., & Ledwidge, M. T. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.002 · Cited by 46
Alirocumab after acute coronary syndrome in patients with a history of heart failure
White, H. D., Schwartz, G. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab804 · Cited by 41
“In CORONA, 5011 patients with NYHA class II–IV ischaemic HF were randomly assigned to receive rosuvastatin 10 mg/day or placebo.(3) Rosuvastatin did not reduce the primary outcome of death from cardiovascular causes, non-fatal MI, or non-fatal stroke.”
InfluentialTsutamoto, T., Sakai, H., 伊部, 邦., Yamaji, M., Kawahara, C., Nakae, I., Fujii, M., Yamamoto, T., & Horie, M. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0222 · Cited by 43
Lipid-lowering therapy: who can benefit
Lewis, S. J. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23113 · Cited by 52
Suzuki, G., Iyer, V., Cimato, T. R., & Canty, J. M. (2008) · Circulation Research · doi:10.1161/circresaha.108.188730 · Cited by 42
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Metadata
- Authors
- Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., Gullestad, L., Hjalmarson, Å., Hradec, J., Jánosi, A., Kamenský, G., Komajda, M., Korewicki, J., Kuusi, T., Mach, F., Mareev, V., McMurray, J. J. V., Ranjith, N., Schaufelberger, M., Vanhaecke, J., van Veldhuisen, D. J., Waagstein, F., Wedel, H., & Wikstrand, J.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-29
- Volume
- 357
- Issue
- 22
- Pages
- 2248-2261
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2126452437
- Cited by
- 1,487
- References
- 27
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 41 · 2023: 43 · 2022: 62 · 2021: 46 · 2020: 63 · 2019: 72 · 2018: 53 · 2017: 75 · 2016: 73 · 2015: 89 · 2014: 96 · 2013: 109 · 2012: 96
- FWCI
- 140.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- rosuvastatin, heart failure with reduced ejection fraction, elderly patients, statins, cardiovascular mortality, cardiovascular hospitalization, LDL cholesterol, high-sensitivity C-reactive protein, statin safety, myocardial infarction, stroke
- MeSH terms
- Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Pyrimidines, Sulfonamides, Systole, Proportional Hazards Models, Single-Blind Method, Treatment Outcome, Myocardial Ischemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.